Prosecution Insights
Last updated: October 02, 2026

Examiner: GULLEDGE, BRIAN M

Tech Center 1600 • Art Units: 1600 1611 1612 1619 1628 1637 1699

This examiner grants 56% of resolved cases

Analysis

Brian M. Gulledge is an examiner in Tech Center 1600 and Art Unit 1600. Across 959 resolved cases, the data shows an allowance rate of 55.8 percent. This 55.8 percent figure provides a baseline for practitioners to understand the probability of a grant. The 959 resolved cases offer a statistically significant look at the examiner's historical tendencies in this biotechnology and organic chemistry center.

The data reveals an interview lift of 26.1 percent. This 26.1 percent lift indicates that an interview is associated with a higher likelihood of allowance compared to the baseline of cases where no interview is conducted. Practitioners may use this metric to evaluate the impact of verbal advocacy. This comparison is a key element of the prosecution strategy for cases in Art Unit 1600.

The median days to allowance for Gulledge is 1231. This 1231-day period serves as a benchmark for the expected duration of successful prosecutions. The combination of the 55.8 percent allowance rate and the 26.1 percent interview lift, within the context of Tech Center 1600, helps in setting expectations for both timing and results.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

55.8%
Allow Rate
-4.2% vs TC avg
988
Total Applications
+26.1%
Interview Lift
1231
Avg Prosecution Days
Based on 959 resolved cases, 2023–2026

Rejection Statute Breakdown

1.7%
§101 Eligibility
13.2%
§102 Novelty
50.0%
§103 Obviousness
21.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18522301 Silicone Mixture for Hair Conditioning Final Rejection The Procter & Gamble Company
18844688 A DRUG NANOCARRIER SYSTEM TO DELIVER A COMBINATION OF TLR AGONISTS AND/OR A LIPOXIN PLUS IMMUNOGENIC CELL DEATH INDUCING CHEMOTHERAPEUTIC AGENTS FOR CANCER IMMUNOTHERAPY Non-Final OA The Regents of the University of California
18250727 SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY Non-Final OA The Regents of the University of California
18700749 CELLULOSE NANOCRYSTAL STABILIZED CHEMICAL COMPOSITION Non-Final OA SYNGENTA CROP PROTECTION AG
18271131 SPRAY-TYPE HYDROGEL Final Rejection SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
18283396 DISINFECTANT COMPOSITION FOR AUTOMOTIVE CARE AND METHODS OF USE Non-Final OA 3M INNOVATIVE PROPERTIES COMPANY
18254064 COSMETIC COMPOSITION COMPRISING A SILICONE, A STARCH AND AT LEAST 3% OF POLYOL, AND COSMETIC TREATMENT PROCESS Final Rejection L'Oréal
18529540 THIOLATED POLYMER GEL WITH INTESTINAL ABSORPTION BARRIER AND USING METHOD THEREOF Non-Final OA National Taiwan University
18267811 MONOMER COMPOSITION AND METHOD FOR PRODUCING SAME, AND COSMETIC OR COSMETIC RAW MATERIAL INCLUDING MONOMER COMPOSITION Non-Final OA DOW TORAY CO., LTD.
18564278 OIL GELLING AGENT AND COSMETIC Non-Final OA SHIN-ETSU CHEMICAL CO., LTD.
18839496 COMPOSITIONS COMPRISING PIROCTONE OLAMINE Non-Final OA CLARIANT INTERNATIONAL LTD.
17910672 CARYOPHYLLENE-CONTAINING AGENT OR COMPOSITION AND VARIOUS APPLICATIONS THEREOF Final Rejection SUNSHO PHARMACEUTICAL CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month